CJC-1295 vs Ipamorelin: Growth Hormone Peptide Comparison
Résumé
CJC-1295 and Ipamorelin represent two different strategies for stimulating growth hormone (GH): CJC-1295 as a GHRH (Growth Hormone Releasing Hormone) analogue and Ipamorelin as a selective GH secretagogue via the ghrelin receptor. They are often studied in combination due to synergistic action.
Propriétés de la substance
What is CJC-1295?
CJC-1295 is a synthetic 30-amino-acid analogue of natural GHRH (Growth Hormone Releasing Hormone). It comes in two forms: with DAC (Drug Affinity Complex), which binds albumin and extends half-life to ~8 days, and without DAC (Modified GRF 1-29), with a half-life of ~30 minutes. It acts through the GHRH receptor in the anterior pituitary.
What is Ipamorelin?
Ipamorelin (NNC 26-0161) is a pentapeptide that acts as a selective ghrelin receptor (GHSR-1a) agonist. It stimulates GH secretion without significant effects on cortisol, ACTH, or prolactin — distinguishing it from older GH secretagogues like GHRP-6.
Mechanism: GHRH vs Ghrelin pathway
CJC-1295 mimics natural GHRH, binding the GHRH receptor and increasing basal GH production. Ipamorelin acts through GHSR-1a (ghrelin pathway), which pulsatilely enhances GH secretion. The two pathways are complementary: GHRH increases GH pulse amplitude, while ghrelin increases pulse frequency.
Why are they studied together?
The combination of CJC-1295 (without DAC) + Ipamorelin is studied because the two mechanisms act synergistically: simultaneous activation of GHRH-R and GHSR-1a produces greater GH elevation than the sum of individual actions. This synergy is documented in in vitro and animal models.
Research data
CJC-1295 with DAC: An open-label study (Teichman et al., 2006) showed prolonged GH and IGF-1 elevation for 6–8 days after a single dose. Ipamorelin: Multiple human studies show dose-dependent GH elevation without significant effects on cortisol or prolactin. Clinical experience is primarily from studies for post-operative ileus.
CJC-1295 with DAC vs without DAC
The DAC version has a long half-life (~8 days) and provides steady GH/IGF-1 elevation, but does not mimic natural pulsatile rhythm. The non-DAC version (mod-GRF 1-29) has a short half-life (~30 minutes) and better mimics pulsatile rhythm, which is why it is preferred in research protocols combined with Ipamorelin.
Safety profile
CJC-1295: Most commonly reported side effects include flushing, redness, mild headache, water retention. The DAC version has been associated with rare serious events in unconfirmed reports. Ipamorelin: Generally well-tolerated in clinical studies, with headache and nausea as the most common side effects. Neither peptide is approved.
Guides associés
Foire aux questions (FAQ)
What is the main difference?
CJC-1295 mimics GHRH (increases basal GH production), while Ipamorelin mimics ghrelin (enhances pulsatile secretion). They act on different receptors.
Are they approved?
No. Neither has regulatory approval. They are used exclusively in research settings.
Why are they used together?
The combination of GHRH-R + GHSR-1a activation produces synergistic GH elevation greater than individual use.
Références & études
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Jimenez-Reina L et al. Interaction of growth hormone releasing hormone (GHRH) and ghrelin on GH secretion from pig pituitary cells. Domest Anim Endocrinol. 2002;22(3):169-178.
Avertissement
This article is exclusively educational for researchers. It does not constitute medical advice.
⚠️ À des fins informatives et éducatives uniquement. Ne constitue pas un avis médical. Nous ne vendons aucun produit. Avertissement